Literature DB >> 3295127

Grade 3 nausea, vomiting, and myelosuppression or progressive, metastatic sarcoma?

R S Benjamin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3295127     DOI： 10.1200/JCO.1987.5.6.833

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study.

Authors:  N Penel; M V Glabbeke; S Mathoulin-Pelissier; I Judson; S Sleijfer; B Bui; P Schoffski; M Ouali; S Marreaud; V Brouste; A Duhamel; P Hohenberger; J-Y Blay
Journal:  Br J Cancer       Date:  2011-04-19       Impact factor: 7.640

2.  Symptom burden, survival and palliative care in advanced soft tissue sarcoma.

Authors:  Nicholas J Gough; Clare Smith; Joy R Ross; Julia Riley; Ian Judson
Journal:  Sarcoma       Date:  2011-12-11

Review 3.  Chemotherapy for metastatic soft tissue sarcomas--another full circle?

Authors:  V H Bramwell
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

4.  Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.

Authors:  S Leyvraz; R Herrmann; L Guillou; H P Honegger; A Christinat; M F Fey; C Sessa; M Wernli; T Cerny; D Dietrich; B Pestalozzi
Journal:  Br J Cancer       Date:  2006-10-10       Impact factor: 7.640

5.  Does palliative chemotherapy really palliate and are we measuring it correctly? A mixed methods longitudinal study of health related quality of life in advanced soft tissue sarcoma.

Authors:  Nicholas Gough; Jonathan Koffman; Joy R Ross; Julia Riley; Ian Judson
Journal:  PLoS One       Date:  2019-09-26       Impact factor: 3.240

6.  Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group.

Authors:  D Bafaloukos; C Papadimitriou; H Linardou; G Aravantinos; P Papakostas; D Skarlos; P Kosmidis; G Fountzilas; H Gogas; C Kalofonos; A M Dimopoulos
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

7.  Management of advanced adult soft tissue sarcoma.

Authors:  Vivien H C Bramwell
Journal:  Sarcoma       Date:  2003
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.